Do analysts prefer CCCC or AADI?

C4 Therapeutics currently has a consensus price target of $7.75, suggesting a potential upside of 110.31%. Given C4 Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe C4 Therapeutics is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score C4 Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate AADI or XFOR?

X4 Pharmaceuticals has a consensus target price of $9.70, indicating a potential upside of 115.32%. Given X4 Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe X4 Pharmaceuticals is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 X4 Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

Do analysts recommend AADI or ABEO?

Abeona Therapeutics has a consensus price target of $19.00, suggesting a potential upside of 164.44%. Given Abeona Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Abeona Therapeutics is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Abeona Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Aadi Bioscience (AADI) Competitors

$4.70 +0.63 (+15.48%)

As of 08/6/2026

Compare

AADI vs. CCCC, XFOR, EBS, RCKT, and ABEO

Should you buy Aadi Bioscience stock or one of its competitors? MarketBeat compares Aadi Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aadi Bioscience include C4 Therapeutics (CCCC), X4 Pharmaceuticals (XFOR), Emergent Biosolutions (EBS), Rocket Pharmaceuticals (RCKT), and Abeona Therapeutics (ABEO). These companies are all part of the "biotechnology" industry.

How does Aadi Bioscience compare to C4 Therapeutics?

C4 Therapeutics (NASDAQ:CCCC) and Aadi Bioscience (NASDAQ:AADI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Aadi Bioscience has a net margin of -246.06% compared to C4 Therapeutics' net margin of -297.76%. C4 Therapeutics' return on equity of -50.68% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-297.76%	-50.68%	-33.22%
Aadi Bioscience	-246.06%	-71.87%	-57.28%

Aadi Bioscience has lower revenue, but higher earnings than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$35.95M	11.33	-$104.99M	-$1.19	N/A
Aadi Bioscience	$25.07M	4.63	-$65.76M	-$2.35	N/A

C4 Therapeutics has a beta of 2.91, suggesting that its stock price is 191% more volatile than the broader market. Comparatively, Aadi Bioscience has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

78.8% of C4 Therapeutics shares are held by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are held by institutional investors. 5.6% of C4 Therapeutics shares are held by company insiders. Comparatively, 37.3% of Aadi Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

C4 Therapeutics currently has a consensus price target of $7.75, suggesting a potential upside of 110.31%. Given C4 Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe C4 Therapeutics is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, C4 Therapeutics had 1 more articles in the media than Aadi Bioscience. MarketBeat recorded 1 mentions for C4 Therapeutics and 0 mentions for Aadi Bioscience. C4 Therapeutics' average media sentiment score of 0.84 beat Aadi Bioscience's score of 0.00 indicating that C4 Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
C4 Therapeutics	Positive
Aadi Bioscience	Neutral

Summary

C4 Therapeutics beats Aadi Bioscience on 12 of the 16 factors compared between the two stocks.

How does Aadi Bioscience compare to X4 Pharmaceuticals?

Aadi Bioscience (NASDAQ:AADI) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

Aadi Bioscience has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Comparatively, X4 Pharmaceuticals has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market.

In the previous week, X4 Pharmaceuticals had 6 more articles in the media than Aadi Bioscience. MarketBeat recorded 6 mentions for X4 Pharmaceuticals and 0 mentions for Aadi Bioscience. X4 Pharmaceuticals' average media sentiment score of 0.34 beat Aadi Bioscience's score of 0.00 indicating that X4 Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Aadi Bioscience	Neutral
X4 Pharmaceuticals	Neutral

Aadi Bioscience has a net margin of -246.06% compared to X4 Pharmaceuticals' net margin of -1,106.30%. Aadi Bioscience's return on equity of -71.87% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
X4 Pharmaceuticals	-1,106.30%	-94.90%	-48.09%

52.1% of Aadi Bioscience shares are held by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are held by institutional investors. 37.3% of Aadi Bioscience shares are held by insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

X4 Pharmaceuticals has a consensus target price of $9.70, indicating a potential upside of 115.32%. Given X4 Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe X4 Pharmaceuticals is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Aadi Bioscience has higher earnings, but lower revenue than X4 Pharmaceuticals. Aadi Bioscience is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	4.63	-$65.76M	-$2.35	N/A
X4 Pharmaceuticals	$35.11M	12.10	-$79.20M	-$4.54	N/A

Summary

X4 Pharmaceuticals beats Aadi Bioscience on 10 of the 16 factors compared between the two stocks.

How does Aadi Bioscience compare to Emergent Biosolutions?

Emergent Biosolutions (NYSE:EBS) and Aadi Bioscience (NASDAQ:AADI) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

Emergent Biosolutions has a net margin of -22.95% compared to Aadi Bioscience's net margin of -246.06%. Emergent Biosolutions' return on equity of 14.83% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Emergent Biosolutions	-22.95%	14.83%	5.89%
Aadi Bioscience	-246.06%	-71.87%	-57.28%

Emergent Biosolutions currently has a consensus target price of $12.00, indicating a potential upside of 139.76%. Given Emergent Biosolutions' stronger consensus rating and higher possible upside, equities research analysts clearly believe Emergent Biosolutions is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emergent Biosolutions	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Emergent Biosolutions has higher revenue and earnings than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than Emergent Biosolutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emergent Biosolutions	$742.30M	0.35	$52.60M	-$3.55	N/A
Aadi Bioscience	$25.07M	4.63	-$65.76M	-$2.35	N/A

78.4% of Emergent Biosolutions shares are owned by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are owned by institutional investors. 6.0% of Emergent Biosolutions shares are owned by company insiders. Comparatively, 37.3% of Aadi Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Emergent Biosolutions has a beta of 2.35, meaning that its share price is 135% more volatile than the broader market. Comparatively, Aadi Bioscience has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market.

In the previous week, Emergent Biosolutions had 15 more articles in the media than Aadi Bioscience. MarketBeat recorded 15 mentions for Emergent Biosolutions and 0 mentions for Aadi Bioscience. Emergent Biosolutions' average media sentiment score of 0.27 beat Aadi Bioscience's score of 0.00 indicating that Emergent Biosolutions is being referred to more favorably in the media.

Company	Overall Sentiment
Emergent Biosolutions	Neutral
Aadi Bioscience	Neutral

Summary

Emergent Biosolutions beats Aadi Bioscience on 13 of the 16 factors compared between the two stocks.

How does Aadi Bioscience compare to Rocket Pharmaceuticals?

Rocket Pharmaceuticals (NASDAQ:RCKT) and Aadi Bioscience (NASDAQ:AADI) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

Rocket Pharmaceuticals has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Rocket Pharmaceuticals' return on equity of -69.61% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket Pharmaceuticals	N/A	-69.61%	-58.63%
Aadi Bioscience	-246.06%	-71.87%	-57.28%

Rocket Pharmaceuticals presently has a consensus price target of $8.71, indicating a potential upside of 148.06%. Given Rocket Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Rocket Pharmaceuticals is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket Pharmaceuticals	3 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.30
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Aadi Bioscience has higher revenue and earnings than Rocket Pharmaceuticals. Aadi Bioscience is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$1.87	N/A
Aadi Bioscience	$25.07M	4.63	-$65.76M	-$2.35	N/A

98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are owned by institutional investors. 21.3% of Rocket Pharmaceuticals shares are owned by insiders. Comparatively, 37.3% of Aadi Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Rocket Pharmaceuticals has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market. Comparatively, Aadi Bioscience has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market.

In the previous week, Rocket Pharmaceuticals had 3 more articles in the media than Aadi Bioscience. MarketBeat recorded 3 mentions for Rocket Pharmaceuticals and 0 mentions for Aadi Bioscience. Rocket Pharmaceuticals' average media sentiment score of 0.25 beat Aadi Bioscience's score of 0.00 indicating that Rocket Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Rocket Pharmaceuticals	Neutral
Aadi Bioscience	Neutral

Summary

Rocket Pharmaceuticals beats Aadi Bioscience on 11 of the 16 factors compared between the two stocks.

How does Aadi Bioscience compare to Abeona Therapeutics?

Aadi Bioscience (NASDAQ:AADI) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

Abeona Therapeutics has a consensus price target of $19.00, suggesting a potential upside of 164.44%. Given Abeona Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Abeona Therapeutics is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Abeona Therapeutics has lower revenue, but higher earnings than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than Abeona Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	4.63	-$65.76M	-$2.35	N/A
Abeona Therapeutics	$5.82M	70.36	$71.18M	$0.97	7.41

In the previous week, Abeona Therapeutics had 6 more articles in the media than Aadi Bioscience. MarketBeat recorded 6 mentions for Abeona Therapeutics and 0 mentions for Aadi Bioscience. Abeona Therapeutics' average media sentiment score of 0.17 beat Aadi Bioscience's score of 0.00 indicating that Abeona Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Aadi Bioscience	Neutral
Abeona Therapeutics	Neutral

Aadi Bioscience has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market. Comparatively, Abeona Therapeutics has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market.

52.1% of Aadi Bioscience shares are owned by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are owned by institutional investors. 37.3% of Aadi Bioscience shares are owned by company insiders. Comparatively, 7.1% of Abeona Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Abeona Therapeutics has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Abeona Therapeutics' return on equity of -53.98% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
Abeona Therapeutics	N/A	-53.98%	-38.52%

Summary

Abeona Therapeutics beats Aadi Bioscience on 14 of the 16 factors compared between the two stocks.

Get Aadi Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AADI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AADI vs. The Competition

Export

Metric	Aadi Bioscience	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$116.08M	$3.64B	$6.96B	$12.95B
Dividend Yield	N/A	3.76%	2.59%	9.93%
P/E Ratio	-2.06	8.42	270.83	25.99
Price / Sales	4.63	1,271.71	663.11	111.01
Price / Cash	N/A	101.37	71.89	50.37
Price / Book	1.10	18.02	13.19	6.22
Net Income	-$65.76M	-$13.22M	$3.45B	$342.55M
7 Day Performance	22.08%	5.53%	4.32%	4.17%
1 Month Performance	16.92%	-3.96%	-1.87%	-1.15%
1 Year Performance	161.11%	57.64%	76.76%	22.24%

Aadi Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AADI Aadi Bioscience	N/A	$4.70 +15.5%	N/A	+129.9%	$116.08M	$25.07M	N/A	40
CCCC C4 Therapeutics	2.2722 of 5 stars	$3.61 +3.1%	$7.75 +114.7%	+85.7%	$386.98M	$35.95M	N/A	150	Upcoming Earnings
XFOR X4 Pharmaceuticals	2.4045 of 5 stars	$4.29 +4.9%	$9.70 +126.1%	+163.9%	$385.77M	$35.11M	N/A	80	News Coverage Earnings Report Gap Up
EBS Emergent Biosolutions	2.0715 of 5 stars	$7.56 +2.0%	$12.00 +58.8%	-12.3%	$382.33M	$742.90M	N/A	2,420	News Coverage Earnings Report
RCKT Rocket Pharmaceuticals	2.5379 of 5 stars	$3.44 +0.9%	$8.71 +153.3%	+17.2%	$372.35M	N/A	N/A	240

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AADI) was last updated on 8/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aadi Bioscience (AADI) Competitors

AADI vs. CCCC, XFOR, EBS, RCKT, and ABEO

How does Aadi Bioscience compare to C4 Therapeutics?

Summary

How does Aadi Bioscience compare to X4 Pharmaceuticals?

Summary

How does Aadi Bioscience compare to Emergent Biosolutions?

Summary

How does Aadi Bioscience compare to Rocket Pharmaceuticals?

Summary

How does Aadi Bioscience compare to Abeona Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AADI vs. The Competition

Aadi Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aadi Bioscience (AADI) Competitors

AADI vs. CCCC, XFOR, EBS, RCKT, and ABEO

How does Aadi Bioscience compare to C4 Therapeutics?

Is CCCC or AADI more profitable?

Which has stronger earnings and valuation, CCCC or AADI?

Which has more volatility & risk, CCCC or AADI?

Do insiders & institutionals hold more shares of CCCC or AADI?

Do analysts prefer CCCC or AADI?

Does the media favor CCCC or AADI?

Summary

How does Aadi Bioscience compare to X4 Pharmaceuticals?

Which has more risk & volatility, AADI or XFOR?

Does the media refer more to AADI or XFOR?

Is AADI or XFOR more profitable?

Do insiders and institutionals believe in AADI or XFOR?

Do analysts rate AADI or XFOR?

Which has higher valuation & earnings, AADI or XFOR?

Summary

How does Aadi Bioscience compare to Emergent Biosolutions?

Is EBS or AADI more profitable?

Do analysts prefer EBS or AADI?

Which has better earnings and valuation, EBS or AADI?

Do insiders & institutionals believe in EBS or AADI?

Which has more volatility & risk, EBS or AADI?

Does the media prefer EBS or AADI?

Summary

How does Aadi Bioscience compare to Rocket Pharmaceuticals?

Is RCKT or AADI more profitable?

Do analysts recommend RCKT or AADI?

Which has better valuation & earnings, RCKT or AADI?

Do insiders and institutionals believe in RCKT or AADI?

Which has more volatility & risk, RCKT or AADI?

Does the media prefer RCKT or AADI?

Summary

How does Aadi Bioscience compare to Abeona Therapeutics?

Do analysts recommend AADI or ABEO?

Which has higher earnings and valuation, AADI or ABEO?

Does the media refer more to AADI or ABEO?

Which has more risk & volatility, AADI or ABEO?

Do insiders and institutionals hold more shares of AADI or ABEO?

Is AADI or ABEO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AADI vs. The Competition

Aadi Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools